Vor Biopharma (VOR) Operating Income (2020 - 2026)
Vor Biopharma (VOR) reported Operating Income of -$35.2 million for Q1 2026, down 5.61% year-over-year from -$37.3 million in Q1 2025, and up 2.22% quarter-over-quarter from -$36.0 million in Q4 2025.
Vor Biopharma (VOR) Operating Income (2020 - 2026) Analysis & Trends
Vor Biopharma (VOR) has 7 years of Operating Income data on file, last reported at -$35.2 million in Q1 2026.
- Operating Income for Q1 2026 came in at -$35.2 million, down 5.61% year-over-year; the trailing twelve-month figure through Mar 2026 was -$373.5 million (down 205.78% YoY), and the FY2025 annual result was -$371.6 million, down 206.67% from the prior year.
- Operating Income rose to -$35.2 million in Q1 2026 per VOR's latest filing, from -$36.0 million in the prior quarter.
- Over five years, Operating Income peaked at -$21.8 million in Q2 2022 and troughed at -$274.3 million in Q2 2025.
- A 5-year average of -$44.0 million and a median of -$30.4 million in 2023 frame the typical range for Operating Income.
- The sharpest annual moves came in 2024 and 2025: Operating Income advanced 19.26% in 2024, then sank 844.67% in 2025.
- A 5-year view of Operating Income shows it stood at -$24.7 million in 2022, then retreated by 13.75% to -$28.1 million in 2023, then decreased by 11.33% to -$31.3 million in 2024, then fell by 14.85% to -$36.0 million in 2025, then climbed by 2.22% to -$35.2 million in 2026.
- Business Quant data shows VOR's Operating Income at -$35.2 million in Q1 2026, -$36.0 million in Q4 2025, and -$28.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -32.68 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -19.70 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.82 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -15.76 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.14 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -65.83 Mn |
| 10 | Vor Biopharma | 627.54 Mn | 627.54 Mn | - | -35.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -35.16 Mn |
| Dec 31, 2025 | -35.96 Mn |
| Sep 30, 2025 | -28.11 Mn |
| Jun 30, 2025 | -274.28 Mn |
| Mar 31, 2025 | -33.29 Mn |
| Dec 31, 2024 | -31.31 Mn |
| Sep 30, 2024 | -28.51 Mn |
| Jun 30, 2024 | -29.04 Mn |
| Mar 31, 2024 | -32.33 Mn |
| Dec 31, 2023 | -28.12 Mn |
| Sep 30, 2023 | -35.32 Mn |
| Jun 30, 2023 | -32.17 Mn |
| Mar 31, 2023 | -30.42 Mn |
| Dec 31, 2022 | -24.73 Mn |
| Sep 30, 2022 | -24.10 Mn |
| Jun 30, 2022 | -21.79 Mn |
| Mar 31, 2022 | -22.80 Mn |
| Dec 31, 2021 | -18.31 Mn |
| Sep 30, 2021 | -18.60 Mn |
| Jun 30, 2021 | -18.38 Mn |